Guardant Health (GH)
(Delayed Data from NSDQ)
$31.75 USD
-1.61 (-4.83%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $31.76 +0.01 (0.03%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth B Momentum C VGM
Price, Consensus and EPS Surprise
GH 31.75 -1.61(-4.83%)
Will GH be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for GH based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for GH
Merus N.V. (MRUS) Reports Q2 Loss, Lags Revenue Estimates
Guardant Health (GH) Moves 6.9% Higher: Will This Strength Last?
GH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Guardant Health (GH) Just Overtook the 20-Day Moving Average
Guardant Health (GH) Now Trades Above Golden Cross: Time to Buy?
Guardant Health (GH) Recently Broke Out Above the 200-Day Moving Average
Other News for GH
Vanguard Health Care Fund Amplifies Stake in Novo Nordisk A/S
Guardant launches Shield colorectal cancer test in U.S.
Guardant launches newly approved colorectal cancer test in U.S.
Guardant Health?s FDA-approved Shield? Blood Test Now Commercially Available in U.S. as a Primary Screening Option for Colorectal Cancer
Guardant Health Outcomes Model Confirms the Public Health Importance of Enhanced Colorectal Cancer Screening Outcomes with High Adherence Strategies